Medication info
Pregabalin 75 mg Capsule

Pregabalin 75 mg Capsule

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Hanpung Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201905662 · Approved 2019.08.12 · Insurance code 658107070

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation.”) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, it may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this drug, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. 72 ⅹ serum creatinine concentration (serum creatinine, mg/dl) *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to a dose administered as an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12-17 years because sufficient safety and efficacy data are not available.

Ingredients

Manufacturer
Hanpung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it is utilized as an adjunctive treatment for partial seizures in patients with epilepsy, helping to alleviate symptoms. It is also effective in relieving symptoms in patients with fibromyalgia. This drug aids in managing pain and seizures related to various neurological disorders, thereby enhancing the quality of life for patients.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation.”) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, it may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this drug, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. 72 ⅹ serum creatinine concentration (serum creatinine, mg/dl) *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to a dose administered as an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12-17 years because sufficient safety and efficacy data are not available.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression or abnormal mood changes occur during use, patients must inform their healthcare provider immediately. Patients with hypersensitivity to any ingredient in this medication or lactose intolerance should not use it, and lactose-containing formulations should not be administered to patients with hereditary lactose metabolism disorders. Diabetic patients should be cautious, as weight gain may necessitate dosage adjustments for blood glucose control medications. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, stop taking the medication immediately. Elderly patients could experience dizziness, drowsiness, or confusion when taking this medication, and care should be taken to ensure safety until they acclimate to these effects. Vision disturbances or changes may occur, and discontinuing the medication could lead to improvement in these symptoms. Withdrawal symptoms such as insomnia, headache, nausea, and anxiety may occur when discontinuing the medication, so consultation with a healthcare provider is necessary. Patients with a history of drug abuse should be particularly cautious, as this medication may carry a high risk of abuse, and monitoring for signs of abuse is advised. Patients with impaired kidney function may require dosage adjustments, and there have been cases of improved kidney function following cessation of treatment. Patients with heart disease should exercise caution when taking this medication, especially those with severe congestive heart failure. Caution should also be observed when taken with opioid analgesics, as there is an increased risk of central nervous system depression, which can lead to serious side effects, such as respiratory suppression. Pregnant women should avoid taking this medication during early pregnancy due to the risk of congenital abnormalities in the fetus, and women of childbearing age should use effective contraception. Lactating women should either avoid breastfeeding while taking this medication or consult with their healthcare provider, as this drug can be passed into breast milk and affect the infant. Caution should be exercised while driving or operating machinery, as this medication may cause dizziness or drowsiness. Overdose of this medication may lead to symptoms such as drowsiness, confusion, and depression, necessitating immediate medical attention, and treatment such as hemodialysis may be required. Keep this medication out of reach of children and avoid transferring it to other containers. If severe rash or allergic reaction occurs, discontinue use immediately and seek medical evaluation.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 214 more
  • loss of consciousness
  • confusion
  • psychiatric disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • agitation
  • depression
  • elation
  • decreased libido
  • insomnia
  • depersonalization
  • paraphilia
  • restlessness
  • anxiety
  • mood disturbances
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • impaired motor coordination
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reflex decrease
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremors of activity
  • syncope
  • confusion
  • hypomotility
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eye swelling
  • vision loss
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibrations
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased leukocyte count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusion states
  • depression
  • agitation
  • restlessness
  • worsening of convulsions
  • ataxia
  • speech disorders
  • sensory abnormalities
  • memory disorders
  • attention disorders
  • constipation
  • gastrointestinal disturbances
  • bloody stools
  • increased BUN
  • difficulty urinating
  • tinnitus
  • skin diseases

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that prevents exposure to air and moisture, at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.